Salicylate reduces cisplatin
nephrotoxicity by inhibition of tumor necrosis factor-[alpha].
By comparison, 80% of patients in the cisplatin
group responded overall, with 38.
All 24 patients had measurable hearing loss that occurred as early as weeks after beginning cisplatin
SQUIRE was an open-label, randomized, multi-center Phase III trial that compared first-line treatment with Portrazza in combination with gemcitabine and cisplatin
to treatment with gemcitabine and cisplatin
alone in patients with metastatic squamous NSCLC.
After the monolayers attained confluency of around 70%, cells were treated with cisplatin
(30 [micro]M) with or without Aa-EE (1 or 5 [micro]g/ml).
By using our cisplatin
formulation, we can increase the drug dosing to almost double," Dr Basu said.
Finally, of the cisplatin
cases, 8 were bilateral and 2 cases were unilateral, for a total of 18 ears.
He and colleagues in London and Manchester examined data for cisplatin
combined with radiotherapy and compared it with that for patients given radiotherapy on its own.
Comment: The clinical use of cisplatin
chemotherapy is limited by severe peripheral neurotoxicity, which occurs in up to 90% of patients receiving a cumulative dose greater than 300 mg/m2 of body surface area.
Damage is much more common with cisplatin
than with a related third-generation platinum compound, oxaliplatin, although the reason has been unknown.
based regimens are considered the standard treatment for advanced NSCLC.
The UK National Cancer Research Institute's Phase III REAL-2 study demonstrated that capecitabine is non-inferior to 5-FU and oxaliplatin is non-inferior to cisplatin
when substituted within the ECF regimen.